Dana-Farber Cancer Institute
Boston, MA
Filters
Save & Share
Clear Filters
Accepting patients
TRIDENT-1
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results
Accepting patients
CARE Study
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials- PI3K Inhibitor
- Tyrosine Kinase (TK) Inhibitor
- CDK6
- Phase 2
Accepting patients
Larotrectinib
A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 1
Accepting patients
LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers
Learn more- Observational Trial
Accepting patients
NCI-COG Pediatric MATCH
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Learn more- ALK Inhibitor
- EphA2 Inhibitor
- Phase 2
Accepting patients
NAUTIKA1: Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer
Learn more- Phase 2